News atai invests $50m in Beckley Psytech Beckley Psytech has announced that it has received substantial strategic investment from Germany-based atai Life Sciences, totalling $50 million, to accelerate the clinica
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.